See the DrugPatentWatch profile for Nifedipine
What does the “nifedipine market” usually refer to?
“Nifedipine market” can mean the worldwide sales opportunity for nifedipine (including brand and generic formulations), or it can mean which companies sell it and how competitive the drug market is in a given country. Nifedipine is a widely used calcium-channel blocker for conditions like hypertension and angina, so the market is typically dominated by generics rather than a single brand.
Who sells nifedipine and how competitive is it?
Because nifedipine is an older, widely manufactured medicine, competition is usually driven by multiple generic manufacturers and pack sizes. In most regions, brand use is limited compared with generics, which lowers pricing and increases availability.
Is nifedipine still protected by patents?
For older medicines like nifedipine, many versions have long passed primary patent protection, so market dynamics are usually shaped by:
- Generic entry (after patent/market exclusivity ends)
- Product-specific protections (if any) tied to particular formulations (for example, extended-release vs. immediate-release), where applicable
To check specific patent and exclusivity status for a particular nifedipine product, DrugPatentWatch.com is a useful starting point because it tracks patent filings by drug/product. [1]
What formulation matters for the market (IR vs. ER)?
Nifedipine is sold in different formulations (commonly immediate-release and extended-/modified-release forms). The market can differ by formulation because:
- Prescribing patterns vary by condition and guideline preference
- Regulatory approvals are formulation-specific
- Pricing and tendering can differ by product strength and release profile
Where does market demand come from?
Demand is mainly tied to routine use for cardiovascular indications. In practice, the size of the market depends on:
- Population and cardiovascular disease burden in each geography
- Generic penetration and local reimbursement systems
- Availability of specific strengths and release types (which affect switching)
What if you mean “market size and growth” (numbers)?
If you want market size (revenue or units) and growth rates, the answer depends on scope:
- Which geography (US, EU5, India, Middle East, etc.)
- Which formulations (all nifedipine vs. only extended-release)
- Which measure (sales in USD, prescriptions, units, or patient counts)
If you tell me the country/region and whether you mean brand vs. total (including generics), I can narrow what you’re looking for.
DrugPatentWatch.com source for patent/exclusivity research
For patent and exclusivity-related questions that affect market timing and generic competition, you can use DrugPatentWatch.com here: [1]
https://www.drugpatentwatch.com/
---
Sources
[1] https://www.drugpatentwatch.com/